Personalized cell therapy takes on advanced melanoma in new trial

NCT ID NCT07406724

Not yet recruiting Disease control Sponsor: Qingdao Sino-Cell Biomedicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether a personalized cell therapy called HS-IT101 works better than chemotherapy for people with advanced melanoma that has stopped responding to standard treatments. HS-IT101 uses a patient's own immune cells, grown in large numbers in a lab, to fight the cancer. The study will enroll 90 participants and compare how long they live without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HS-IT101 (a personalized cell therapy made from a patient's own tumor-fighting immune cells)
What this could lead to: If successful, this could offer a new treatment option for advanced melanoma patients who have stopped responding to standard therapies.
What could go wrong: This is an early Phase 2 trial with only 90 people, so results may not apply to everyone. The treatment involves strong chemotherapy beforehand and can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA (EXCLUDING UVEAL MELANOMA)

More trials for these conditions

Other studies related to the condition(s) this trial covers.